Turner Syndrome Clinical Trial
Official title:
Vosoritide for Treatment of Short Stature in Girls With Turner Syndrome
Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the short-stature homeobox-containing (SHOX) gene. Growth hormone (GH) is an approved therapy for this condition, although not associated with GH deficiency, and benefits are modest. Vosoritide, a C-type natriuretic peptide (CNP) analog, targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. We hypothesize that patients with TS and short stature will respond to vosoritide treatment leading to increased growth velocity. This study will enroll pre-pubertal girls with TS who are either naïve to GH or have had a poor response to GH therapy. All subjects will be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes. Annualized growth velocity (AGV) on vosoritide will be compared to AGV in the 6-18 months prior to initiation of vosoritide based on historical data available in the medical record. Subjects with a positive response to therapy will be given the option to continue in the extension phase of the study during which they will continue to receive vosoritide until growth cessation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
| Completed |
NCT01419249 -
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
|
Phase 4 | |
| Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
| Recruiting |
NCT04948658 -
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
|
||
| Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT02787486 -
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
|
||
| Completed |
NCT00877942 -
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
|
N/A | |
| Completed |
NCT00825617 -
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
|
N/A | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
| Terminated |
NCT00419107 -
Beta Cell Function in Women With Turner Syndrome
|
N/A | |
| Active, not recruiting |
NCT00625001 -
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
|
N/A | |
| Completed |
NCT00029159 -
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
|
Phase 3 | |
| Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT00471731 -
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
|
N/A | |
| Completed |
NCT00256126 -
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
|
Phase 4 | |
| Completed |
NCT03181230 -
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
|